Posted by Michael Wonder on 14 Jun 2023
Tixagevimab and cilgavimab for the prevention of COVID-19 disease
14 June 2023 - NICE has published final evidence-based recommendations on the use of tixagevimab and cilgavimab (Evusheld) for the prevention of COVID‑19 disease in adults.
Tixagevimab and cilgavimab is not recommended for the pre‑exposure prophylaxis of COVID‑19 disease in adults who are not currently infected with SARS‑CoV‑2 and who have not had a known recent exposure to someone infected with SARS‑CoV‑2, and who are unlikely to have an adequate immune response to COVID‑19 vaccination, or for whom COVID‑19 vaccination is not recommended.
